摘要
脓毒症是目前急危重症病死率较高的疾病之一,对其早期识别、早期干预可在一定程度上改善不良终点事件的发生,降低病死率。降钙素原(PCT)、C-反应蛋白(CRP)作为经典的脓毒症生物标志物,在脓毒症的早期识别和预后风险评估中存在一定的局限性。可溶性白细胞分化抗原14亚型(sCD14-ST)作为近年新发现的生物标志物,其在脓毒症的诊断和预后评估方面有着较好的应用前景。本文就Presepsin对儿童脓毒症诊断及预后评估中的价值进行综述,以期开展更多的研究指导其应用于临床。
Sepsis is one of the diseases with a high mortality rate in acute and critical cases, and early identification and intervention can improve the occurrence of adverse endpoints and reduce the mortality rate to a certain extent. Procalcitonin (PCT) and C-reactive protein (CRP), as classic biomarkers of sepsis, have certain limitations in the early recognition and prognostic risk assessment of sepsis. Soluble leukocyte differentiation antigen 14 subtype (sCD14-ST), as a newly discovered biomarker in recent years, has a good application prospect in the diagnosis and prognosis evaluation of sepsis. This article reviews the value of Presepsin in the diagnosis and prognosis assessment of sepsis in children, in order to carry out more clinical studies to guide its clinical application.
出处
《临床医学进展》
2024年第4期582-587,共6页
Advances in Clinical Medicine
